Literature DB >> 4042294

The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction.

A S Lew, P Laramee, B Cercek, L Rodriguez, P K Shah, W Ganz.   

Abstract

We studied the influence of the following variables on the time interval from initiation of an intravenous infusion of 750,000 U of streptokinase until reperfusion (reperfusion time) in 140 consecutive patients with an evolving acute myocardial infarction: (1) the rate of infusion of streptokinase, (2) the duration of chest pain before initiation of treatment, (3) patient age, (4) patient sex, (5) location of infarction, (6) history of previous myocardial infarction, and (7) pretreatment pathologic Q waves. The time of reperfusion was recognized by clinical criteria that were completely concordant with the anatomic findings in all 119 patients in whom patency or occlusion of the artery of infarction was established at delayed angiography (n = 116) or at postmortem examination (n = 3). The mean reperfusion time for the 129 patients for whom data were available was 49 +/- 36 min. The reperfusion time was inversely related to the rate of infusion of streptokinase (r = .41, p less than .001), but this effect of infusion rate appeared to plateau at rates of greater than 500 U/kg/min. In the 64 patients receiving infusions at rates of 500 U/kg/min or less, the mean reperfusion time was 60 +/- 40 min, whereas in the 58 patients receiving the drug at rates greater than 500 U/kg/min it was 35 +/- 22 min (p less than .001). The duration of chest pain before treatment was the only other studied variable found to influence the reperfusion time, but only at infusion rates of less than 250 U/kg/min (r = .6, p less than .01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4042294     DOI: 10.1161/01.cir.72.5.1053

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.

Authors:  J D Gemmill; K J Hogg; J M Burns; A P Rae; F G Dunn; R Fears; H Ferres; R Standring; H Greenwood; D Pierce
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction.

Authors:  Gabriel Tatu-Chitoiu; Cristina Teodorescu; Monica Dan; Petre Capraru; Manuela Guran; Oana Istratescu; Alexandrina Tatu-Chitoiu; Aurelia Bumbu; Maria Dorobantu
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 3.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

4.  A history of streptokinase use in acute myocardial infarction.

Authors:  Nikhil Sikri; Amit Bardia
Journal:  Tex Heart Inst J       Date:  2007

5.  Streptokinase versus alteplase in acute myocardial infarction.

Authors:  H S Friedman
Journal:  J R Soc Med       Date:  1996-08       Impact factor: 18.000

Review 6.  Aspect of thrombolytic therapy: a review.

Authors:  Md Ramjan Ali; Mohammad Salim Hossain; Md Ariful Islam; Md Saiful Islam Arman; Golam Sarwar Raju; Prianka Dasgupta; Tasnim Fariha Noshin
Journal:  ScientificWorldJournal       Date:  2014-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.